Potential Benefits of Itopride in the Management of Patients With Metabolic Associated Fatty Liver Disease (MAFLD)
NCT ID: NCT05966025
Last Updated: 2023-10-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE2
60 participants
INTERVENTIONAL
2023-12-28
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Sodium Glucose Cotransporter Inhibitors Fatty Liver Disease Patients Fatigue Assessment
NCT05694923
Follow-up of NAFLD Patients With MRI-PDFF
NCT04910178
A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease
NCT02927314
The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease
NCT05364684
Impact of NAFLD vs MAFLD Stigma on Quality of Life in Egyptian Patients
NCT06503068
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
control group
• control group Weight reduction and life style modification(modification in diet like decrease lipids intak).pateints will recieve their conventional therapy
conventional therapy
will taken by patient in control group
interventions: drug itopride
• itopride group Weight reduction and life style modification and receive (itopride) 100 mg once dialy for 24 weeks plus their conventional therapy
Itopride
itopride will be taken by pateints one time per day by dose 100 mg
conventional therapy
will taken by patient in control group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Itopride
itopride will be taken by pateints one time per day by dose 100 mg
conventional therapy
will taken by patient in control group
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with comorbidites like hypertension,diabetes,dyslipidemia
Exclusion Criteria
* cystic fibrosis, coeliac disease
* suspicion of muscular dystrophy, alpha-1-antitrypsin deficiency
* metabolic inherited diseases
* autoimmune hepatitis, drug toxicity and drugs known to induce steatosis (e.g. valproate, amiodarone orprednisone).
* Patients were also excluded if body weight and carbohydrate metabolism were altered by the use of parenteral nutrition
* protein malnutrition
* previous gastrointestinal surgery
* structural abnormalitiesof the gastrointestinal tract or neurological impairment.
* the use of nonsteroidal anti-inflammatory drugs,antibiotics,sglt2,dpp4,statins,glp1
* Patient with age below 18 or above 60
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beni-Suef University
OTHER
October 6 University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Maha youssif
Maha Youssif Fekry
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hoda m rabea, A Professor
Role: PRINCIPAL_INVESTIGATOR
Beni-suaf university
Yasmine m madney, Lecturer
Role: PRINCIPAL_INVESTIGATOR
Beni-suaf university
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Maha Youssif Fekry
Giza, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
REC-H-PhBSU-23006
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.